跳至主要内容
附件 III 条目 21 已修订 17 十月 2010

QUININE

Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)- its salts

QUININE 列于附件 III,只能在本记录所示条件下使用。 本记录中的最大浓度:(a) 0.5% (as quinine base) (b) 0.2% (as quinine base)。

限用物质— 附件 III, 欧盟法规 1223/2009
最大浓度: (a) 0.5% (as quinine base) (b) 0.2% (as quinine base)
条目: 21

记录详情

最大浓度

(a) 0.5% (as quinine base) (b) 0.2% (as quinine base)

INCI 词汇表名称

QUININE

化学名称

Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)- its salts

化学名称 / IUPAC 名称

(8S,9R)-6'-Methoxycinchonan-9-ol

监管信息

法规

(EC) 2009/1223

查看该法案设定的所有条目

已识别的成分

关键数据

附件
条目编号
21

化学身份与性质

CAS 130-95-0 的 PubChem 二维化学结构
CAS 130-95-0PubChem CID 3034034

Quinine

Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as a non-narcotic analgesic, an antimalarial and a muscle relaxant. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. — ChEBI

IUPAC 名称
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
分子式
C20H24N2O2
分子量
324.4 g/mol
精确质量
324.183778013 Da
XLogP3
2.9
拓扑极性表面积
45.6 Ų
氢键供体
1
氢键受体
4
共价单元
1
已定义的立体中心
4

又称

ChinineChinin(-)-Quinine(8S,9R)-Quinine6'-Methoxycinchonidine(R)-(-)-quinine6-Methoxycinchoninechininum
另有 16 个已报告名称
quininaRezquinChininum purum(8S,9R)-6'-Methoxycinchonan-9-ol(R)-(-)-Quinine, 6-methoxycinchonidineA7V27PHC7ACHEBI:15854(8-alpha,9R)-6'-Methoxycinchonan-9-olNSC-192949(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-(R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanolQuinsonQuinsul(R)-((1S,2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)(6-methoxyquinolin-4-yl)methanol(R)-((2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)-(6-methoxyquinolin-4-yl)methanol
外部数据库标识符

来自其他科学数据库的证据

NIH PubChem PUG-View
标识符精确匹配3034034

Attributed physical-property, hazard, environmental and use annotations.

  • Signal: Danger 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (22.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (28.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (99.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (28.4%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334 (83.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 201 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
  • Signal: Warning 来源: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] 来源: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) 来源: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Signal: Danger 来源: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H315: Causes skin irritation [Warning Skin corrosion/irritation]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 来源: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) 来源: Hazardous Substances Data Bank (HSDB)
  • Health Effects: It is usual for quinine in therapeutic doses to cause cinchonism; in rare cases, it may even cause death (usually by pulmonary edema). Quinine can worsen hemoglobinuria, myasthenia gravis and optic neuritis. It can cause paralysis if accidentally injected into a nerve, and is extremely toxic in overdose[Wikipedia] 来源: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Quinine is a bulky, white, amorphous powder or crystalline alkaloid, used as medication: non-narcotic analgesics; antimalarial; central muscle relaxants. It is also used as flavor in carbonated beverages. HUMAN EXPOSURE AND TOXICITY: Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes, angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug. Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria. Visual impairment can range 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

QUININE 的清单链接

清单 Restriction reference
参考 37459

QUININE

CAS: 130-95-0
EC: 205-003-2

该记录的直接匹配结果有限,因此同时显示附件 III 中的相邻条目。

附件 III 22
同一附件中的相邻记录

RESORCINOL

CAS: 108-46-3
EC: 203-585-2
附件 III 18
同一附件中的相邻记录

NITROMETHANE

CAS: 75-52-5
EC: 200-876-6
附件 III 17
同一附件中的相邻记录

SODIUM NITRITE

CAS: 7632-00-0
EC: 231-555-9
附件 III 16
同一附件中的相邻记录

1-Naphthol

CAS: 90-15-3
EC: 201-969-4
附件 III 16
同一附件中的相邻记录

1-NAPHTHOL

CAS: 90-15-3
EC: 201-969-4

附件 III 对 QUININE 意味着什么

QUININE 是欧盟化妆品法规 1223/2009 附件 III 中的限用物质。其在化妆品中的使用仅限于上方条目所列的特定条件,包括适用的浓度限值、产品类型限制和必须标示的警示语。

在配方中使用该物质时,必须同时满足所有条件——最大浓度、产品范围和警示标签。满足其中一项条件并不能免除其他条件。

本记录与 1 个 CosIng 清单成分相关联,便于名称和标识符的交叉引用。 本页还显示 12 条相关附件记录,其标识符、附件逻辑或命名模式存在重叠。

合规核查清单

  • 确保配方浓度不超过:(a) 0.5% (as quinine base) (b) 0.2% (as quinine base)
  • 确认产品类型相符:(a) Hair rinse-off products (b) Hair leave-on products
  • 将使用条件记录在产品信息档案 (PIF) 中。

常见问题

QUININE 作为限用物质列于欧盟法规 1223/2009 的附件 III。只能在条目规定的条件下使用,包括上方所示的任何最大浓度、产品类型限制和必须标示的警示语。

CAS 130-95-0 是化学文摘社 (Chemical Abstracts Service) 分配给 QUININE 的唯一数字标识符。在化妆品合规工作中,CAS 编号用于在监管数据库、原料规格书和安全评估报告之间交叉引用该物质。如果同一物质在不同条件下或不同附件中出现,多个欧盟附件条目可能共用同一 CAS 编号。

最大浓度 (a) 0.5% (as quinine base) (b) 0.2% (as quinine base) 适用于即用型化妆品中该物质的浓度。当该物质作为混合物的一部分供应时,计算必须计入配方中所有来源的贡献。合计浓度不得超过所述限值。

使用本站的 INCI 检查器工具粘贴您的完整成分表 (INCI),并对照所有附件 II–VI 条目进行扫描。该工具会突出显示与限用、禁用或致敏原标记记录相匹配的成分。这有助于对成品配方或原料声明进行快速合规筛查。

附件 III 记录 QUININE 的来源说明

本页概述欧盟委员会公开化妆品资料中 QUININE 的一条附件 III 记录,并在可用时补充关联的清单或标识符匹配。

请使用本记录页面查看 QUININE 的附件 III 条件,但任何最终监管决定都应对照现行官方附件措辞和来源文件确认。

工具与后续步骤

检查您的配方

粘贴完整的 INCI 成分表,一次性检出 QUININE 及其他被标记的欧盟附件记录。

INCI 检查器

条目对比

将 QUININE 与另一条附件记录并排对比,查看限制、浓度和附件归属的差异。

对比

浏览附件

查看附件 III 中的所有记录,并对比该附件中各物质的监管条件。

打开附件 III